FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGENGet Free Report) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 7,380,000 shares, an increase of 6.6% from the April 30th total of 6,920,000 shares. Based on an average trading volume of 2,150,000 shares, the short-interest ratio is currently 3.4 days.

FibroGen Trading Up 1.6 %

FGEN traded up $0.02 during trading hours on Monday, hitting $1.22. The stock had a trading volume of 422,882 shares, compared to its average volume of 2,501,382. The company’s fifty day simple moving average is $1.40 and its 200 day simple moving average is $1.33. FibroGen has a 1 year low of $0.33 and a 1 year high of $19.47.

FibroGen (NASDAQ:FGENGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.02). The company had revenue of $55.90 million during the quarter, compared to the consensus estimate of $41.00 million. As a group, research analysts forecast that FibroGen will post -1.05 EPS for the current year.

Insider Buying and Selling at FibroGen

In related news, CEO Thane Wettig acquired 50,000 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were acquired at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the purchase, the chief executive officer now owns 470,178 shares in the company, valued at $898,039.98. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.98% of the company’s stock.

Institutional Investors Weigh In On FibroGen

Several large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC grew its holdings in FibroGen by 81.2% during the 3rd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biopharmaceutical company’s stock valued at $6,810,000 after buying an additional 3,536,000 shares in the last quarter. Acadian Asset Management LLC purchased a new position in FibroGen during the 3rd quarter valued at about $1,391,000. Primecap Management Co. CA grew its holdings in FibroGen by 7.7% during the 3rd quarter. Primecap Management Co. CA now owns 14,724,968 shares of the biopharmaceutical company’s stock valued at $12,706,000 after buying an additional 1,047,380 shares in the last quarter. Pennant Investors LP purchased a new position in FibroGen during the 4th quarter valued at about $681,000. Finally, Assenagon Asset Management S.A. grew its holdings in FibroGen by 49.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,226,857 shares of the biopharmaceutical company’s stock valued at $1,922,000 after buying an additional 739,166 shares in the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. According to MarketBeat.com, FibroGen presently has a consensus rating of “Hold” and an average price target of $2.00.

View Our Latest Analysis on FibroGen

About FibroGen

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Read More

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.